ZyVersa Therapeutics, Inc.

Corporate News Releases

Jan 6, 2021 • 12:55 PM EST ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in the 39th Annual J.P. Morgan Healthcare Conference 2021, January 11th - 14th

Nov 16, 2020 • 7:08 AM EST ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020

Oct 12, 2020 • 7:08 AM EDT Review Article, Authored by ZyVersa Therapeutics' Esteemed Scientific Advisors, Demonstrates the Role of Inflammasomes in the Exacerbated Immune Response Associated with COVID-19 Infection (Just Published in Frontiers in Immunology)

Sep 8, 2020 • 7:08 AM EDT Journal of Neuroinflammation Article Highlights the Role of Inflammasomes in the Pathogenesis of Multiple Sclerosis, and Mentions the Potential for ASC Inhibitor, IC 100, to Interfere with Inflammasome Signaling at Multiple Points in the Inflammatory Pathway

May 5, 2020 • 1:07 PM EDT Journal of Neuroinflammation Article Shows ZyVersa's Inflammasome Inhibitor, IC 100, Improves Functional Outcomes in an Animal Model of Multiple Sclerosis

Jan 30, 2020 • 7:08 AM EST ZyVersa Therapeutics Featured in Business Worldwide Magazine's Winter Edition as One of the 20 Most Innovative Companies to Watch

Jan 20, 2020 • 7:08 AM EST ZyVersa Therapeutics Releases Video Demonstrating How Inflammasomes Stimulate and Perpetuate Inflammation, and How a Novel Inflammasome Inhibitor, IC 100, Has Potential to Control Chronic Damaging Inflammation Associated with Inflammatory Diseases

Jan 6, 2020 • 7:08 AM EST ZyVersa Therapeutics' CEO, Stephen C. Glover to Attend the 38th Annual J.P. Morgan Healthcare Conference 2020

Dec 18, 2019 • 4:00 PM EST Business Worldwide Magazine Names ZyVersa Therapeutics in Twenty Most Innovative Companies to Watch

Nov 13, 2019 • 7:08 AM EST ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the Stifel 2019 Healthcare Conference